TELO Stock Overview
A pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Telomir Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.29 |
| 52 Week High | US$20.72 |
| 52 Week Low | US$3.11 |
| Beta | 0 |
| 11 Month Change | 0.94% |
| 3 Month Change | -37.92% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -14.20% |
Recent News & Updates
Shareholder Returns
| TELO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 28.4% | -0.3% | -2.3% |
| 1Y | n/a | 12.0% | 16.7% |
Return vs Industry: Insufficient data to determine how TELO performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TELO performed against the US Market.
Price Volatility
| TELO volatility | |
|---|---|
| TELO Average Weekly Movement | 14.0% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TELO's share price has been volatile over the past 3 months.
Volatility Over Time: TELO's weekly volatility has decreased from 24% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 5 | Chris Chapman | telomirpharma.com |
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022.
Telomir Pharmaceuticals, Inc. Fundamentals Summary
| TELO fundamental statistics | |
|---|---|
| Market cap | US$126.14m |
| Earnings (TTM) | -US$18.84m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.7x
P/E RatioIs TELO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TELO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.84m |
| Earnings | -US$18.84m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.3% |
How did TELO perform over the long term?
See historical performance and comparison